04 Oct, EOD - Indian

SENSEX 81688.45 (-0.98)

Nifty 50 25014.6 (-0.93)

Nifty Bank 51462.05 (-0.74)

Nifty IT 41912.5 (0.36)

Nifty Midcap 100 58474.45 (-0.93)

Nifty Next 50 74620.25 (-1.10)

Nifty Pharma 23094.7 (-0.36)

Nifty Smallcap 100 18758.65 (-1.02)

04 Oct, EOD - Global

NIKKEI 225 38635.62 (0.22)

HANG SENG 22736.87 (2.82)

S&P 5807.5 (0.80)

Login/Signup
LOGIN HERE
Cancel

Jubilant Pharmova Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 530019 | NSE Symbol : JUBLPHARMA | ISIN : INE700A01033 | Industry : Pharmaceuticals |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
10-Jul-2024 19-Jul-2024 Quarterly Results Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/07/2024 inter alia to consider and approve Intimation of Board Meeting -July 19 2024 The Company has submitted to the Stock Exchange the Outcome of Board Meeting held on July 19, 2024 Unaudited Financial Results for June 30, 2024 (As per BSE Announcement Dated on 19/07/2024)
22-May-2024 29-May-2024 Final Dividend Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 inter alia to consider and approve Intimation of Board Meeting and recommendation of Final Dividend if any. Outcome of Board Meeting (As Per BSE Announcement Dated on: 29/05/2024)
26-Mar-2024 26-Mar-2024 Change in Directors Outcome of the Board Meeting held on March 26, 2024 Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby inform you that based on the recommendations of the Nomination, Remuneration & Compensation Committee, the Board of Directors of the Company at its meeting held on March 26, 2024 at 11:00 A.M. (IST) and concluded at 11:40 A.M. (IST), appointed Dr. Harsh Mahajan (DIN: 00824227) and Ms. Shivpriya Nanda (DIN: 01313356), as an Additional Director (Non-Executive, Independent) on the Board of the Company w.e.f April 1, 2024 for an initial term of five (5) years i.e. upto March 31, 2029, subject to approval of the shareholders to be obtained within three (3) months hereof. Further, Mr. Srinivasan Sridhar (DIN: 00004272), Ms. Sudha Pillai (DIN: 02263950) and Dr. Ashok Misra (DIN: 00006051), Independent Directors of the Company shall complete their second term on March 31, 2024 and accordingly cease to be an Independent Director on Board of the Company with effect from the closing hours of March 31, 2024. The composition of the Board of Directors of the Company is in compliance with the requirements prescribed under the Companies Act, 2013 and SEBI Listing Regulations. Change in Independent Directors of the Company
23-Jan-2024 02-Feb-2024 Quarterly Results Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/02/2024 inter alia to consider and approve Board Meeting Intimation for unaudited standalone and consolidated financial results of the Company for the Quarter and Nine months ended December 31 2023 Unaudited Financial Results Q3 FY 2024 alongwith Limited Review Report (As Per BSE Announcement Dated on: 02/02/2024)
19-Oct-2023 27-Oct-2023 Quarterly Results Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2023 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30 2023. Unaudited standalone & Consolidated financial Results for Q2 FY 2024 Change in Directors. Disclosure as per attachment. (As per BSE Announcement Dated on 27/10/2023) Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2023 published on October 28, 2023 in MINT (English) and HINDUSTAN (Hindi). (As per BSE Announcement Dated on 30/10/2023)
26-Jun-2023 19-Jul-2023 Quarterly Results Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/07/2023 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2023. Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2023 (As Per BSE Announcement Dated on 19.07.2023)
21-May-2023 29-May-2023 Accounts Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2023 inter alia to consider and approve Jubilant Pharmova Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2023inter alia to consider and approve Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31 2023; and Recommendation of Dividend for the Financial Year ended March 31 2023. Dividend Declaration (As per BSE Announcement Dated on 29/05/2023) We enclose disclosure pertaning to Change in Board of Directros and KMP (As Per BSE Announcement Dated on 30/05/2023)
25-Jan-2023 03-Feb-2023 Quarterly Results Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2023 inter alia to consider and approve Consideration of inter-alia Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31 2022 In terms of Regulation 33 read with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that Board of Directors of Jubilant Pharmova Ltd at its meeting held today i.e. Friday, February 03, 2023 considered and approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended December 31, 2022. Copy of the unaudited financials results for the quarter ended December 31, 2022 alongwith Limited Review Reports issued by the Statutory Auditors on the Unaudited Financial Results (Standalone and Consolidated) for the said period and Press Release/Presentation on aforesaid financials is enclosed herewith. The Board Meeting commenced at 11:15 a.m. and concluded at 12.50 p.m. All the above mentioned documents will be simultaneously posted on the Company''s website at www.jubilantpharmova.com. You are requested to take note of the same. (As per BSE Announcement Dated on 03/02/2023) Appointment of Statutory Auditors (As Per BSE Announcement Dated on 04.02.2023)
13-Oct-2022 21-Oct-2022 Quarterly Results Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/10/2022 inter alia to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (the Listing Regulations) we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday October 21 2022 to inter-alia consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30 2022. In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2022 have been approved by the Board of Directors of the Company at its meeting held today at 11:45 a.m. and concluded at 1.30 p.m. Pursuant to the applicable provisions of the Listing Regulations, we enclose the following: 1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2022; 2. Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said period; and 3. Copies of the Press Release and Presentation. We request you to take the same on record. (As per BSE Announcement Dated on 21/10/2022) Newspaper publication of financial results for quarter and half year ended September 2022 (As Per BSE Announcement Dated on 22/10/2022)
26-Jul-2022 02-Aug-2022 Quarterly Results Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2022 inter alia to consider and approve Consideration of Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2022 In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2022 were approved by the Board of Directors of the Company at its meeting held today at 11:15 a.m. and concluded at 12.45 p.m. Pursuant to the applicable provisions of the Listing Regulations, we enclose the following: 1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2022; 2. Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter; and 3. Copies of the Press Release and Presentation. (As Per BSE Announcement Dated on 02.08.2022)
02-Aug-2022 01-Aug-2022 Employee Stock Option JLL Employees Stock Option Plan 2018 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Nomination, Remuneration and Compensation Committee (the 'Committee') of the Company has, at its meeting held on Monday, August 1, 2022, has granted stock options as per the attached details.
20-May-2022 27-May-2022 Final Dividend Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2022 inter alia to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (the Listing Regulations) we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday May 27 2022 to inter-alia consider: 1. Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31 2022; and 2. Recommendation of Dividend for the Financial Year ended March 31 2022. This is for information and record. In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2022 were approved by the Board of Directors of the Company at its meeting held today at 1:15 p.m. and concluded at 4.15 p.m. Pursuant to the applicable provisions of the Listing Regulations, we enclose the following: 1. The Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2022; 2. Audit Reports for Standalone and Consolidated Financial Results; 3. Copies of the Press Release and Presentation. We declare that the Reports of Auditors are with unmodified opinion with respect to the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2022. Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company has, at its meeting held today i.e. on May 27, 2022, recommended a dividend of Rs. 5 (Rupees Five only) per equity share of Re. 1 each for the year ended March 31, 2022. The dividend, if approved by the shareholders at the ensuing Annual General Meeting of the Company, will be paid/ despatched on or before September 7, 2022. We request you to take the same on record. (As Per BSE Announcement Dated on 27.05.2022) In continuation of our letter dated May 27, 2022, we enclose copies of the Audited Consolidated Financial Results for the quarter and year ended March 31, 2022 published on May 28, 2022 in MINT (English) and HINDUSTAN (Hindi). We request you to take the same on record. (As Per BSE Announcement Dated on 28.05.2022)
27-Jan-2022 04-Feb-2022 Quarterly Results Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2022 inter alia to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (the Listing Regulations) we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday February 4 2022 to inter-alia consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended December 31 2021. This is for your information and record. In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended December 31, 2021 were approved by the Board of Directors of the Company at its meeting held today at 12.15 p.m. and concluded at 3.20 p.m. Pursuant to the applicable provisions of the Listing Regulations, we enclose the following: 1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended December 31, 2021; 2. Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter; and 3. Copies of the Press Release and Presentation. We request you to take the same on records. (As Per BSE Announcement Dated on 04/02/2022)
14-Oct-2021 22-Oct-2021 Quarterly Results Quarterly Results Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/10/2021 ,inter alia, to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, October 22, 2021, to inter-alia consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2021. Dear Sirs, In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2021 have been approved by the Board of Directors of the Company at its meeting held today at 1:15 p.m. and concluded at 2.45 p.m. Pursuant to the applicable provisions of the Listing Regulations, we enclose the following: 1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2021; 2. Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said period; and 3. Copies of the Press Release and Presentation. (As Per BSE Announcement dated on 22.10.2021)
15-Jul-2021 23-Jul-2021 Quarterly Results Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2021 ,inter alia, to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, July 23, 2021, to inter-alia consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2021. In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of Jubilant Pharmova Limited ('JPM'), at its meeting held on July 23, 2021, has approved the demerger of the Active Pharmaceutical Ingredients (API) undertaking of Jubilant Generics Limited ('JGL' - a wholly owned subsidiary of the Company) and vesting of the same with JPM, on a going concern basis ('Proposed Demerger'), to be implemented through a scheme of arrangement between JGL and JPM and their respective shareholders and creditors under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ('Proposed Scheme'). The details as required to be disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated September 9, 2015, are enclosed at 'Annexure A'. Kindly take the above information on record. (As Per BSE Announcement Dated on 23.07.2021)
1 2